Literature DB >> 6636537

Respiratory syncytial virus glycoproteins.

D M Lambert, M W Pons.   

Abstract

The proteins of respiratory syncytial (RS) virus were analyzed by SDS-polyacrylamide gel electrophoresis. Eight virion structural proteins with molecular weights of 180,000, 89,000, 48,000, 42,000, 34,000, 28,000, 25,000, and 21,000 were identified. These proteins were given tentative designations of L (180,000), G (89,000), F1 (48,000), NP (42,000), P (34,000), M (28,000), Vp25 (25,000), and F2 (21,000). The 89,000-, 48,000-, and 21,000-dalton polypeptides were glycosylated and could be purified on lentil-lectin sepharose columns. All three glycoproteins could be immunoprecipitated from extracts of infected cells but not from uninfected cells, suggesting that they are viral specified. The host cell affected the apparent molecular weights of the largest and smallest glycosylated polypeptides possibly by differences in glycosylation. The 48,000- and 21,000-dalton glycopolypeptides were disulfide linked subunits of a 68,000-dalton glycoprotein that was seen on unreduced gels. The 68,000-dalton glycoprotein was thus similar to the fusion (F) protein of paramyxoviruses. Treatment of infected cultures with tunicamycin, a drug that blocks glycosylation, inhibited syncytial formation and resulted in over a 1000-fold reduction of extracellular infectious virus. Virions purified from tunicamycin-treated cells had reduced amounts of all three glycosylated proteins. No new forms of these proteins were conclusively identified, suggesting that unglycosylated forms of RS glycoproteins were not incorporated into virion membranes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6636537     DOI: 10.1016/0042-6822(83)90128-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.

Authors:  R A Olmsted; B R Murphy; L A Lawrence; N Elango; B Moss; P L Collins
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

2.  Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides.

Authors:  S L Wechsler; D M Lambert; M S Galinski; M W Pons
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

3.  Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  J J Gorman; B L Ferguson; D Speelman; J Mills
Journal:  Protein Sci       Date:  1997-06       Impact factor: 6.725

4.  Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus.

Authors:  D A Hendricks; K McIntosh; J L Patterson
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

5.  Calcium requirement for syncytium formation in HEp-2 cells by respiratory syncytial virus.

Authors:  M S Shahrabadi; P W Lee
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

6.  Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus.

Authors:  P L Collins; Y T Huang; G W Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 7.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Sequence analysis of the respiratory syncytial virus phosphoprotein gene.

Authors:  M Satake; N Elango; S Venkatesan
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

9.  Analysis of polypeptides synthesized in bovine respiratory syncytial virus-infected cells.

Authors:  S K Mallipeddi; S K Samal; S B Mohanty
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

10.  The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript.

Authors:  P L Collins; G W Wertz
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.